News for Syndax Pharmaceuticals, Inc. (SNDX)

Insights from the First Quarter of 2025 N-PORT Filing Vanguard Health Care Fund (Trades, Portfolio) recently submitted its N-PORT filing for the first quarter

**media[653412]**

**media[652830]**

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals ( SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies,

**media[640245]**

U.S. stocks were lower, with the Nasdaq Composite falling more than 50 points on Tuesday. Shares of Agilysys, Inc. AGYS rose sharply during Tuesday's session f...

”“ Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, K

**media[625375]**

- Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization o

Syndax Pharmaceuticals (SNDX) has appointed Dr. Nicholas Botwood as its new Head of Research and Development and Chief Medical Officer. Dr. Botwood joins the co

Synlogic, Inc. (SNDX) is set to participate in a meeting organized by B. Riley in New York on May 19. This engagement forms part of the company's strategy to sh

PR NewswireAUSTIN, Texas, May 8, 2025 Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna SethAUSTIN, Texas, May 8, 2025 /P

**media[618064]**

On May 6, 2025, Scotiabank's analyst George Farmer issued an update on Syndax Pharmaceuticals (SNDX), maintaining a 'Sector Perform' rating. Notably, the price

In a recent report dated May 6, 2025, Guggenheim analyst Michael Schmidt has reiterated the Buy rating for Syndax Pharmaceuticals (SNDX). The firm maintains its

Revvvi Forge Net Revenue: $20 million in the first full quarter of the launch.Nick Timbo Net Revenue: $13.6 million from the first two months of the joint laun

Exploring the robust pipeline and commercial strategies of Syndax Pharmaceuticals Inc (SNDX).Delving into the financial intricacies and growth trajectory of SN

May 05, 2025 / 08:30PM GMTOperator Good day, everyone, and welcome to the Syndax first-quarter 2025 earnings conference call. Today's call is being recorded. (O

Syndax Pharmaceuticals reports robust revenue growth, indicating strong market entry. Analysts predict significant upside potential for the stock over t